ivacaftor; lumacaftor - Profile

What are the generic drug sources for ivacaftor; lumacaftor and what is the scope of freedom to operate?

Ivacaftor; lumacaftor is the generic ingredient in one branded drug marketed by Vertex Pharms Inc and is included in two NDAs. There are twenty-three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ivacaftor; lumacaftor has four hundred and sixty-one patent family members in thirty-six countries.

Summary for ivacaftor; lumacaftor

International Patents:	461
US Patents:	23
Tradenames:	1
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ivacaftor; lumacaftor

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ivacaftor; lumacaftor

Dosage:

GRANULE;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ivacaftor; lumacaftor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-003	Sep 2, 2022		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-003	Sep 2, 2022		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-003	Sep 2, 2022		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-003	Sep 2, 2022		RX	Yes	No					Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-003	Sep 2, 2022		RX	Yes	No					Y

EU/EMA Drug Approvals for ivacaftor; lumacaftor

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vertex Pharmaceuticals (Ireland) Limited	Orkambi	lumacaftor, ivacaftor	EMEA/H/C/003954Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene.	Authorised	no	no	no	2015-11-19

International Patents for ivacaftor; lumacaftor

Country	Patent Number	Title	Estimated Expiration
Australia	2009296271	Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
South Korea	20120061875
New Zealand	708598
Japan	4960708
Cyprus	1119945

Supplementary Protection Certificates for ivacaftor; lumacaftor

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3170818	2020/035	Ireland		PRODUCT NAME: A COMBINATION OF (A) 3-(6-(1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5- YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR) AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151124
1773816	2015/036	Ireland		PRODUCT NAME: N-(5-HYDROXYL-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723
3170818	PA2020525,C3170818	Lithuania		PRODUCT NAME: (A) 3-(6-(1-(2,2-DIFLUORBENZO(D)(1,3)DIOKSOL-5-IL)CIKLOPROPANKARBOKSAMIDO)-3-METILPIRIDIN-2-IL)BENZENKARBOKSIRUGSTIES IR (B) N-(5-HIDROKSI-2,4-DITERT-BUTILFENIL)-4-OKSO-1H-CHINOLIN-3-KARBOKSAMIDO ARBA FARMACINIU POZIURIU PRIIMTINOS N-(5-HIDROKSI-2,4-DITERT-BUTIL-FENIL)-4-OKSO-1H-CHINOLIN-3-KARBOKSAMIDO DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/15/1059 20151119
2404919	1690018-5	Sweden		PRODUCT NAME: 3-6-1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5- YL)CYCLOPROPANECARBONYLAMINO-3-METHYLPYRIDIN-2-YLBENZOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR AN ESTER THEREOF.; REG. NO/DATE: EU/1/15/1059 20151124
1773816	237 5014-2015	Slovakia		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERC-BUTYL-FENYL)-4-OXO- -1H-CHINOLIN-3-KARBOXAMID (IVACAFTOR); REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120725

Investment Scenario, Market Dynamics, and Financial Trajectory for Ivacaftor and Lumacaftor

Last updated: February 3, 2026

Summary

This report evaluates the investment landscape, market conditions, and financial prospects for the combination drug ivacaftor and lumacaftor, used in cystic fibrosis (CF) treatment. It synthesizes current production data, market size, competitive environment, patent landscape, regulatory considerations, and future growth drivers. The analysis offers insights into key revenue streams, risks, and strategic opportunities, supporting stakeholders in informed decision-making.

---

1. Overview of Ivacaftor and Lumacaftor

Component	Mechanism of Action	Market Authorization	Primary Indication
Ivacaftor	CFTR potentiator, improves gating function of cystic fibrosis transmembrane conductance regulator (CFTR)	FDA (2012), EMA (2012)	Gating mutations in CF
Lumacaftor	CFTR corrector, enhances processing and trafficking of CFTR	FDA (2015), EMA (2015)	Homozygous F508del mutation in CF
Combination	Enhances CFTR function in F508del homozygous cystic fibrosis patients	Approved (2015+), marketed as Orkambi	CF with F508del mutation

Manufacturers: Vertex Pharmaceuticals dominates production, with occasional licensing agreements.

Key patents protecting the combination expire progressively through 2030s, with some secondary patents extending exclusivity.

---

2. Market Size and Revenue Trajectory

Current Market Estimates (2022–2023)

Parameter	Data / Source	Notes
Global cystic fibrosis market size (2023)	~$6.4 billion [1]	Expected to grow at 7.2% CAGR through 2028
Ivacaftor/Lumacaftor (Orkambi) sales (2022)	~$1.6 billion [2]	Dominant CF drug, with significant geographic coverage
Market penetration (US, EU, ROW)	US (~50%), EU (~30%), ROW (~20%)	US leads, driven by insurance coverage and diagnosis rates
Price per treatment course (US)	~$150,000–$250,000	Varies by country, healthcare coverage policies

Revenue Forecast, 2023–2028

Year	Estimated Global Sales	CAGR	Key Drivers
2023	~$1.7 billion	—	Increased diagnosis, insurance coverage expansion
2024	~$1.83 billion	7.2%	Introduction of new formulations, improved access
2025	~$1.96 billion	7.2%	Competitive landscape stabilization
2026	~$2.10 billion	7.1%	Generic entry risk mitigated, patent protections
2027	~$2.25 billion	7.1%	New indications, expanded markets
2028	~$2.41 billion	7.1%	Continued pipeline growth

Source: Market research reports [1], [2]

---

3. Market Dynamics and Competitive Landscape

Key Competitive Players

Company	Drug(s)	Market Share % (2023)	Notes
Vertex Pharmaceuticals	Orkambi (ivacaftor/lumacaftor), Symdeko, Trikafta	~70%	Dominates CF market, extensive R&D pipeline
AbbVie	Renvela, Humira (non-CF but relevant for pipeline)	N/A	Competitor in biotech licensing
Galapagos/AbbVie	Preserved in early stages	N/A	Potential future competitor

Market Drivers

• Increasing diagnosis rates due to newborn screening programs.
• Expansion of indications (e.g., age groups, genotypes).
• Pricing models and insurance reimbursements, especially in USA.
• Emergence of novel therapies (e.g., Trikafta, next-gen correctors).

Market Challenges

• High treatment costs limiting affordability.
• Patent expiries and biosimilar threats, reducing pricing power.
• Competitive pipeline aiming for combination therapies.

Regulatory and Policy Environment

• US and EU reimbursement policies favor innovative, high-cost therapies but scrutinize price justification.
• Orkambi’s patents' expiration leads to increased biosimilar entries post-2030.
• Orphan drug designation provides market exclusivity until at least 2025–2028, with extensions.

---

4. Patent Landscape and Intellectual Property

Patent Type	Protection Period	Key Patent(s)	Expiration Year(s)	Implication
Composition	20 years from filing	Patents on drug molecule	2030–2035	Market exclusivity, generic risk post-expiry
Method of Use	Variable	Combination patents	2028–2032	Extends patent protection, patents on treatment methods
Formulation	15–20 years	Extended formulations	2030–2040	Product differentiation

Note: Secondary patent strategies, such as new formulations or delivery methods, are pivotal in extending exclusivity.

---

5. Financial Trajectory and Investment Opportunities

Revenue Drivers

• Ongoing sales volume growth driven by diagnosis and adherence.
• Pricing recoveries from increased healthcare budgets.
• Pipeline products: Next-generation CFTR modulators under development; promising to replace or supplement current therapies.

Investment Risks

• Patent expiry-induced revenue decline possible post-2030.
• Market competition from biosimilars and emerging therapies.
• Regulatory delays impacting new formulations’ approval.
• Pricing pressures in healthcare systems with cost containment policies.

Strategic Opportunities

• Expansion into juvenile and pediatric markets.
• Development of combination therapies for broader mutation coverage.
• Geographic expansion, especially into emerging markets.
• Licensing and partnership models for pipeline expansion.

Projected Financial Metrics (2023–2028)

Metric	2023 Estimate	2028 Estimate	CAGR	Notes
Total Sales (Global)	~$1.7B	~$2.41B	7.1%	Based on growth projections
R&D Investment (% of sales)	~15%	~12%	n/a	Increasing focus on next-generation therapies
Patent Portfolio Valuation	Stable with patents expiring	Decline post-expiry		Strategic patenting essential for valuation

Source: Industry analysis and company disclosures.

---

6. Comparison with Similar CF Products

Product	Innovator	Market Share (%)	Price Range (per treatment)	Patent Status	Key Differentiator
Trikafta (Elexacaftor/Tezacaftor/Ivacaftor)	Vertex Pharmaceuticals	~50% (2023)	~$300,000/year	Patent until ~2035	Broader mutation coverage, preferred for advanced cases
Orkambi	Vertex	~70% (marketed as combination)	~$150,000–$250,000/year	Expiring early 2030s	Established, high efficacy for F508del homozygous CF
Kalydeco (Ivacaftor)	Vertex	Significant base	$250,000/year	Expiring soon in some jurisdictions	First CFTR potentiator, now top-up from newer agents

---

7. Regulatory Trends and Impact

Trend	Impact	Relevant Policies/Regulations
Accelerated approvals	Faster access, earlier revenue realization	FDA’s Priority Review, EMA’s Conditional Approval
Orphan drug designation	Market exclusivity, tax credits	US Orphan Drug Act (1983), EU Orphan Regulation
Cost-effectiveness evaluations	Reimbursement hurdles	NICE (UK), IQWiG (Germany)
Patent extensions and defense strategies	Extended exclusivity	Secondary patents, complementarity strategies

---

8. Future Outlook and Growth Drivers

• Pipeline Innovation: Vertex’s expansion into triple combinations (e.g., Trikafta) is anticipated to capture faster growth.
• Market Expansion: Entry into India, China, and other emerging markets is critical.
• Personalized Medicine: Increasing genomic diagnosis will drive market segmentation.
• Regulatory Environment: Favorable in US and EU but cautious towards excessive pricing.
• Competing Approaches: Gene editing, mRNA therapies may disrupt the CF market long-term but currently remain in experimental stages.

---

Key Takeaways

• Market Position: Ivacaftor/lumacaftor remains a dominant CF therapy with around $1.6 billion in annual sales, with growth driven by diagnosis expansion and pipeline advancements.
• Patent Strategy: Patent protections, extending into the mid-2030s, offer vital exclusivity, though biosimilar threats are imminent post-expiry.
• Revenue Growth: Expected CAGR of approximately 7.1% through 2028, supported by new markets and indications.
• Competitive Landscape: Dominated by Vertex, with shifting dynamics due to biosimilar entries and emerging combination therapies.
• Investment Risks: Patent expiries, high treatment costs, and regulatory hurdles could impact long-term revenues.
• Opportunities: Pipeline innovation, expansion into emerging markets, and strategic licensing present avenues for sustained growth.

---

FAQs

Q1: What is the patent expiration timeline for ivacaftor and lumacaftor?
A1: Patents on ivacaftor and lumacaftor are primarily expected to expire between 2030 and 2035, with secondary patents and formulations possibly extending protection until 2040.

Q2: How is the competitive landscape evolving with biosimilar entrants?
A2: Biosimilar competition is likely post-2030, especially in markets with strong patent protections expiring. Vertex actively employs patent strategies and pipeline diversification to mitigate revenue losses.

Q3: What are the key drivers for revenue growth beyond 2023?
A3: Expansion into pediatric populations, new geographic markets, approvals of next-generation agents, and broader mutation coverage underpin projected growth.

Q4: Are there regulatory challenges that could impact sales?
A4: Yes. Pricing pressures, health policy changes, and cost-effectiveness assessments could influence reimbursement, especially in Europe and other markets with strict evaluation policies.

Q5: What strategic moves should investors watch for in the next five years?
A5: Monitor pipeline developments (e.g., triple combination therapies), patent litigation or extensions, geographic expansion plans, and emerging competition, including biosimilars and gene therapies.

---

References

[1] MarketResearch.com, "Cystic Fibrosis Treatment Market," 2023.
[2] IQVIA, "Global Sales Data for CF Therapies," 2022.
[3] Vertex Pharmaceuticals Annual Reports, 2018–2022.
[4] European Medicines Agency, "Regulatory Approvals for CF Therapies," 2022.
[5] FDA, "Drug Approvals and Patent Data," 2023.